Although DMTs do not appear to target MS symptoms, oral, sustained-release dalfampridine has been shown to improve walking in patients with MS. This was demonstrated by an increase in walking speed. It is the only medication approved by the FDA for this indication for patients with MS.
Cognitive dysfunction is a major problem that affects quality of life, family and social relationships, and employment. Cognitive dysfunction also can affect memory, comprehension, problem-solving, and speech. Treatment for cognitive dysfunction in patients with MS should include supportive therapy provided by speech pathologists or occupational therapists. In addition, depression may contribute to cognitive dysfunction and should be treated if it is diagnosed. No pharmacologic therapy has been shown clearly to improve cognitive impairment in MS. For example, a multicenter randomized clinical trial in patients with MS who had memory impairment found that donepezil was no better than placebo for improving memory.
Pharmacologic treatment of spasticity includes baclofen, which is particularly useful for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity in patients with MS who have reversible spasticity. Baclofen is effective in most cases, is inexpensive, and is titrated easily from 10 mg/d to 140 mg/d in divided doses. Adverse effects include fatigue and weakness. Dantrolene sodium acts directly on skeletal muscle to decrease spasticity in patients with MS. This agent is used less frequently than baclofen because of its hepatotoxicity at higher doses and numerous drug interactions.
Learn more about symptomatic treatment of MS.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Michelle H. Cameron, Kerstin Hellwig. Fast Five Quiz: Key Aspects of Multiple Sclerosis Treatment - Medscape - Jun 30, 2022.